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• sEH levels are increased in AD human brain and in murine models  
• Inhibition of sEH reduces oxidative stress and inflammation in murine AD models 
• AD hallmarks in AD mice models are reduced after treatment with sEH inhibitors 
• sEH inhibitors improve cognition in AD mice models 




The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical 
therapeutic effects in several peripheral inflammatory-related diseases, with three compounds  
in clinical trials. However, the role of this enzyme in the neuroinflammation process has been 
largely neglected. Herein, we disclose the pharmacological validation of sEH as a novel target 
for the treatment of Alzheimer’s Disease (AD). Evaluation of cognitive impairment and 
pathological hallmarks were used in two models of age-related cognitive decline and AD using 
three structurally different and potent sEH inhibitors as chemical probes. sEH is upregulated in 
brains from AD patients. Our findings supported the beneficial effects of central sEH inhibition, 
regarding reducing cognitive impairment, neuroinflammation, tau hyperphosphorylation 
pathology and the number of amyloid plaques. This study suggests that inhibition of 
inflammation in the brain by targeting sEH is a relevant therapeutic strategy for AD. 
 




Chronic inflammation is recognized as a key player in both the onset and progression of 
Alzheimer’s Disease (AD) (1-3). Indeed, 16% of the investment in ongoing clinical trials for AD is 
related to inflammation (4). Neuroinflammation is intimately linked to the oxidative stress 
associated with AD (5,6), controlling the interactions between the immune system and the 
nervous system (7,8). However, several antioxidant therapies and non-steroidal anti-
inflammatory drugs have failed in clinical trials. Therefore, it is of vital importance to expand 
the scope towards novel targets, preferably related to several pathophysiological pathways of 
the disease (9). 
Epoxyeicosatrienoic acids (EETs) mediate vasodilatation, reduce inflammation, attenuate 
oxidative stress and block the pathological endoplasmic reticulum (ER) stress response (10,11). 
The soluble epoxide hydrolase enzyme (sEH, EC 3.3.2.10, EPHX2), widely expressed in relatively 
high abundance in the murine and human brains (12,13), converts EETs and other epoxyfatty 
acids (EpFA) to their corresponding dihydroxyeicosatrienoic acids (DHETs), whereby 
diminishing, eliminating, or altering the beneficial effects of EETs (14) (Fig. 1).  
Considering that several lines of evidence underline a broad involvement of signaling by EETs 
and other EpFA in the central nervous system (CNS) function and disease (15,16) and that lack 
of sEH by genetic deletion improve the signs of AD in a mouse model (17), we hypothesized 
that brain penetrant sEH inhibitors (sEHI) would stabilize EETs in the brain, resulting in a 
reduction of reactive oxygen species (ROS) and diminished neuroinflammation and 
neurodegeneration, leading to a positive outcome in AD. To this end, we studied the 
neuroprotectant role mediated by sEHI in two models ofL AD; the Senescence-accelerated 
mouse prone 8 (SAMP8) and 5XFAD mice model. Because SAMP8, a paradigm of late-onset AD 
and cognitive impairment in age, is characterized by oxidative stress, neuroinflammation, tau 
hyperphosphorylation and proamilodogenic APP processing, but lacks of b-amyloid (βA) 
plaques (18-22), we studied plaque load and cognitive impairment in 5XFAD, a mouse model of 
early-onset AD, to unveil the effect of sEHI on this AD hallmark. (23-24)  
 
2. Methods 
Details of the experimental protocols, including chemicals, animals, novel object recognition 
test (NORT), biochemical and molecular methods, target engagement, drug properties 
characterization and statistical analysis, are given in Supplemental information. 
3. Results  
3.1. Changes in sEH expression in hippocampus from AD patients, SAMP8 and 5XFAD 
The key question was to determine whether sEH expression differs from healthy to pathological 
conditions. Results demonstrated that sEH levels were higher in AD patients brain (Braak III and 
V) in comparison with healthy individuals (Table S1 and Fig. 2A). Moreover, sEH expression was 
also elevated in SAMP8 and 5XFAD hippocampus in reference to their respective controls (Fig. 
2B). 
3.2. On-target drug inhibition of sEH 
We evaluated three structurally different sEH inhibitors as chemical probes (25): TPPU (UC1770, 
IC50 for human sEH = 3.7 nM) (26), AS-2586114 (IC50 for human sEH = 0.4 nM) (27), and UB-EV-
52 (IC50 for human sEH = 9 nM) (28) (Fig. 2C). Previous pharmacokinetic data suggest that TPPU, 
a very well characterized sEH inhibitor, can enter into the brain (29). It is known that AS-
2586114 has a prolonged action in vivo and an ability to cross the blood-brain barrier (BBB) (30-
31). UB-EV-52 is a new inhibitor somewhat related with previously reported adamantane-
derived sEH inhibitors such as t-AUCB (32) and the clinically studied AR9281 (UC1153) (33). To 
determine whether UB-EV-52 possesses drug-like characteristics, we performed in vitro ADMET 
assays. We found that UB-EV-52 has excellent solubility (>100 µM at 37 °C in 5% DMSO: 95% 
PBS buffer), good microsomal stability (Table S2), and does not inhibit drug metabolizing 
cytochromes or the hERG channel (Table S3). Of relevance, some cytochromes are potential off-
target effects of sEH (Fig. 1), since they are situated upstream in the arachidonic acid cascade. 
UB-EV-52 showed less than 5% inhibition of the studied cytochromes (CYP1A2, CYP2C9, 
CYP2C19, CYP3A4 and CYP2D6) at 10 µM (Table S3). As a preliminary assessment of brain 
permeability, UB-EV-52 was subjected to the parallel artificial membrane permeation assay-BBB 
(PAMPA-BBB), a well-established in vitro model of passive transcellular permeation (34). UB-EV-
52 was predicted to be able to cross the BBB (Table S4), which anticipates its ability to enter the 
brain. In order to characterize the toxicity of UB-EV-52, we evaluated cell viability in human 
neuroblastoma SH-SY5Y cells, using an MTT assay for cell metabolic activity and a propidium 
iodide stain assay for cell death. In both assays, UB-EV-52 showed no cytotoxicity at 1, 10, 50 
and 100 µM (Table 1). 
To evaluate whether sEH is the direct binding target of the inhibitors in brain tissue, we 
performed an in vivo thermal shift assay (CETSA) (35). The results showed a significant shift in 
the sEH melting curve in the hippocampus of CD-1 mice orally treated with TPPU, AS-2586114 
and UB-EV-52, demonstrating in vivo compound-induced target stabilization, providing also 
evidence of central action (Fig. 2D). 
To demonstrate that the tested compounds reduced sEH activity, we measured levels of 
regulatory lipid mediators in the cortex of treated and control SAMP8 mice.  As shown in Fig. 
S1, the level of pro-inflammatory lipid mediators in cortex such as PGD2 and TXB2 are higher in 
the control group. At the same time, the anti-inflammatory epoxy fatty acids, including those 
from Ƴ-linoleic acid (EpODE) and other polyunsaturated fatty acids are all higher in treated 
groups, especially in TPPU treated group. These differences also verified the target engagement 
of inhibition of sEH in vivo.  
Once demonstrated that the compounds tested were able to inhibit sEH at the brain level, we 
evaluated the pathological hallmarks and the cognitive impairment associated with AD in 
SAMP8 and 5XFAD. 
 
3.3. sEH inhibitors reduce biomarkers of inflammation, oxidative stress and endoplasmic 
reticulum stress 
Indicators of brain neuroinflammation were determined after oral treatment with TPPU (5 
mg/kg/day), AS-2586114 (7.5 mg/kg/day), and UB-EV-52 (5 mg/kg/day) (Fig. 3A and Fig. S2). 
The three inhibitors reduced gene expression and brain protein levels of the pro-inflammatory 
cytokines IL-1b (Interleukin-b), CCL3 (C-C motif ligand 3) and, importantly, TNF-a (Tumor 
necrosis factor-α) in SAMP8 (Fig. 3B) and in 5XFAD (data not shown). IL-1b is intimately involved 
in neuroinflammatory processes in the CNS (34) and its activity is thought to be closely tied to 
the process of memory consolidation (34, 35). Chemokines play a critical role in phagocytic 
activity. Concretely, CCL3 is expressed in astrocytes and is described as a component of the 
inflammasome complex (36). Of note, TNF-a is not only involved in AD-related brain 
neuroinflammation (37, 38), but also contributes to amyloidogenesis via β-secretase regulation 
(39, 40). Additionally, these results suggest an involvement of the two main inflammasome-
signalling pathways, NF-kβ and NLRP3 (41). 
To investigate the influence of the sEH inhibitors in the oxidative stress process, we determined 
the concentration of hydrogen peroxide in the brain of SAMP8 mice. The three inhibitors 
significantly reduce hydrogen peroxide (Fig. 3C). Moreover, determination of the brain 
oxidative machinery was addressed by evaluating gene expression of Hmox1, Aox1 and protein 
levels of SOD1 (Fig. 3C). Hmox1 (antioxidant activity) (42) was significantly increased by UB-EV-
52 and TPPU, but not by AS-2586114 (Fig. 3C). qPCR analysis also demonstrated that treated 
SAMP8 mice had lower Aox1 expression (Fig. 3C). Aox1 controls the production of hydrogen 
peroxide and, under certain conditions, can catalyze the formation of superoxide (43). 
Furthermore, SOD1 (antioxidant activity) protein levels were significantly increased in all 
treated groups (Fig. 3C), indicating a reinforcement of the antioxidant response after treatment 
with sEHI (44). By contrast, in 5XFAD, a model with reduced oxidative stress, no significant 
changes were determined in oxidative stress parameters evaluated (data not shown). 
It is known that the ER stress plays a role in the pathogenesis of neurodegenerative diseases, 
including AD (45), and sEHI attenuate activation of the ER stress response (10). Therefore, we 
measured the levels of the ER stress sensors ATF-6 and IRE1α (Fig. 3D). Especially, UB-EV-52 
was able to reduce the levels of either protein. Furthermore, we evaluated XBP1, a major 
regulator of the unfolded protein response, which is induced by ER stress (46). XBP1 was 
significantly reduced by UB-EV-52 and slightly decreased by AS-2586114, but not by TPPU (Fig. 
3D). Altogether, these results suggest that the inhibition of sEH protects against oxidative stress 
and the associated ER stress in the brain. 
 
3.4. sEH inhibitors modify the two main physio-pathological hallmarks of AD 
The brains of patients with AD contain two main physio-pathological hallmarks: tangles of 
hyperphosphorylated tau protein and βA plaques. As mentioned, considering that SAMP8 has 
disturbances in tau hyperphosphorylation and APP processing but lacks βA plaques, 5XFAD was 
used to support the protective effect of sEHI in AD hallmarks studied.  On the one hand, after 
oral treatment of SAMP8 and 5XFAD mice with TPPU (5 mg/kg/day), AS-2586114 (7.5 
mg/kg/day), and UB-EV-52 (5 mg/kg/day), sEH inhibition provoked a reduction of the tau 
hyperphosphorylated species (Ser396 and Ser404), especially Ser404, (Fig. 4A and 4B) in 
agreement with the idea that oxidative stress can promote tau hyperphosphorylation and 
aggregation (47-48). On the other hand, we examined the ability of the sEHI to modify the 
amyloid processing cascade. While the 5XFAD transgenic mouse model develops early 
aggressive hallmarks of amyloid burden and cognitive loss (49), SAMP8 is characterized by an 
abnormal amyloid precursor protein (APP) processing, with a misbalance to the amyloidogenic 
pathway. Importantly, C-terminal fragments (CTF) levels are strongly implicated in 
neurodegeneration and the cognitive decline process in SAMP8 (21,22). We observed a 
substantial decrease in the ratio of CTFs/APP protein levels in both mice models after treatment 
with sEHI (Fig. 4C and 4D). In addition, an increase of the sAPPα, and a decrease of sAPPβ 
supported that sEHI are able to shift the APP processing towards the non-amyloidogenic 
pathway, thereby reducing the probability of increasing βA aggregation. Finally, treatment of 
5XFAD mice with sEHI had a strong effect in reducing the number of βA plaques stained with 
Thioflavin-S (by an average of 40%) (Fig. 4E), indicating the prevention of amyloid burden in a 
model characterized by βA plaque formation at early ages as two months. 
 
 3.5. sEH inhibitors reduce cognitive impairment 
To demonstrate the efficacy on the cognitive decline of the sEH inhibitors, we performed a 
NORT to obtain a measure of cognition for short- and long-term memory. Treatment of both 
murine models with the three sEH inhibitors drastically increased the Discrimination Index (DI). 
The significant increase indicates clear preservation of both memories (Figs. 5A and 5B). In both 
models, we add a comparator arm of mice treated with donepezil, which is a standard of care in 
the treatment of AD. As expected, donepezil treatment (5 mg/kg/day) also shifted the DI to 
values significantly higher than zero. Remarkably, in all the conditions, the sEH inhibitors 
reduced cognitive decline better than donepezil. 
 
4. Discussion  
Our results suggest that the pharmacological stabilization of EETs in the brain has the potential 
to address multiple etiologies and physio-pathological processes of AD, i.e., neuroinflammation, 
ER stress and oxidative stress, increasing the chances of success of future therapies based on 
sEH inhibition. Although the decisive role of sEH inhibition in multiple inflammation-related 
diseases has been studied, only a few investigations have been conducted about its crucial role 
in the neuroinflammation process (15, 16, 30). Besides, the question of if neuroinflammation is 
the malicious driver or ‘just’ a consequence still represents an important conundrum in the AD 
field. Our findings reinforce the idea that neuroinflammation might drive the pathogenic 
process in AD. A partial correlation calculation has demonstrated that the anti-inflammatory 
effects of sEH inhibitors correspond with changes in AD hallmarks, slowing the progression of 
the disease and pushing up the cognitive capabilities in the studied animal models (Fig S3-S4 
and Table S5-S6).  
A characteristic feature of acute inflammatory processes is a general increase in the levels of 
classic proinflammatory eicosanoids (prostaglandins, leukotrienes and thromboxanes). In 
neurodegenerative diseases, there is a basal, chronic and silent inflammation that is more 
related to a disbalance in pro-inflammatory and anti-inflammatory cytokines, such as those 
studied IL-1β (36), CCL3 (49) and TNFα,  as well as by acting on different mechanisms implied in 
neurodegeneration (e.g., increase of the oxidative stress, increase in the glutamate pathway, 
among others). Importantly in our landscape, bA activates inflammasomes that in turn, mediate 
IL-1β maturation in microglial cells (49). This allowed us to anticipate different biological and 
therapeutic outcomes for sEH inhibition than for the COX and LOX pathway inhibition.  
Two structurally different sEH inhibitors have proven to be safe in human clinical trials for other 
peripheral indications (AR9281 for hypertension and GSK2256294 for diabetes mellitus, chronic 
pulmonary obstructive disease and subarachnoid hemorrhage)(26, 50) A third inhibitor, 
EC5026, is in human safety trial on a clinical path to chronic pain. This fact, undoubtedly, 
accelerates the development of new sEHI for the treatment of AD and avoids uncertainties 
about the possibility of angiogenic effects when inhibiting sEH. Of relevance, for this study, we 
have employed three structurally different sEH inhibitors, supporting the hypothesis that the 
biological outcomes observed are not due to off-target effects related to a particular inhibitor. 
In summary, we have demonstrated that sEH levels are altered in AD mouse models and, more 
importantly, in the brain of AD patients. We have further shown that the inhibition of sEH has a 
plethora of beneficial central effects, such as reducing inflammation, ER stress, oxidative stress 
markers, p-Tau pathology and the amyloid burden. Consequently, sEHI improve the functional 
efficacy endpoint for cognitive status in neurodegeneration and AD animal models.  
The anti-inflammatory effect of sEHi has been demonstrated in different pathologies [16, 17, 
30]. Nevertheless, considering the results obtained in this work, we cannot rule out the 
beneficial effects of inhibition of sEH by regulating the processes of proteostasis and OS. Those 
effects should be implicated in the β-amyloid plaque removal and tau hyperphosphorylation 
reduction. Based on the results presented in this work, we firmly believe that inhibitors of sEH 
could represent an entirely new stand-alone treatment for the treatment of AD. However 
herein, we do not demonstrate, since is it beyond the scope of this study, if inhibition of sEH 
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Fig. 1. The arachidonic acid cascade. The arachidonic acid (AA) cascade is a group of metabolic 
pathways in which AA and other polyunsaturated fatty acids are the central molecules. 
Metabolism via the cyclooxygenase (COX) and lipoxygenase (LOX) pathways gives rise to 
largely pro-inflammatory and pro-algesic metabolites. Both pathways have been 
pharmaceutically targeted. CYP enzymes either hydroxylate or epoxidize AA leading to 
hydroxyeicosatetranoic acids (HETEs) or epoxyeicosatrienoic acids (EETs), respectively. 
The latter compounds, which are endowed with potent anti-inflammatory properties, 
are rapidly subjected to hydrolysis to their corresponding diols by the soluble epoxide 
hydrolase (sEH) enzyme. Inhibitors of sEH block this degradation and stabilize EETs levels 
in vivo (14). They also reduce the corresponding diols which have some inflammatory 
properties. Major CYPs that oxidize AA are listed in the figure, but many others make a 
contribution.    
 
Fig. 2. Soluble epoxide inhibition and its relevance in AD. (A) Immunoblot of sEH (EPHX2) of 
human brains from AD patients (Braak stage III-V). Groups were compared by Student t-
test (n = 4-7). *p<0.05 vs. non-demented. (B) Immunoblot of sEH (EPHX2) in the 
hippocampus of SAMP8 mice (groups were compared by Student t-test, n = 12-14, 
**p<0.01 vs. SAMR1) and 5xFAD mice (groups were compared by Student t-test, n = 12-
14, ****p<0.0001 vs. Wt). (C) Chemical structure of the sEH inhibitors employed. (D) 
CETSA experiments to monitor brain target engagement. Groups were compared by 
Student t-test or Two-Way ANOVA and post-hoc Dunnett’s, n = 3 per group, *p<0.05, 
**p<0.01 and ***p<0.001 vs. Control. 
 
Fig. 3. Role of sEH inhibitors in neurodegenerative biomarkers. (A) Scheme of experimental 
procedures in in vivo experiments. (B) Gene expression of neuroinflammatory markers 
(Il-1β, Tnf-α, and Ccl3) and protein levels of proinflammatory cytokines IL-1β, TNF-α, and 
CCL3 in the hippocampus of SAMP8 mice after treatment with sEH inhibitors.  (C) 
Oxidative stress measured by hydrogen peroxide concentration in homogenates of the 
hippocampus. Representative gene expression of Hmox1 and Aox1 and representative 
Western blot and quantification of protein levels for (antioxidant enzyme) SOD1 in the 
hippocampus of SAMP8 mice after treatment with sEH inhibitors. (D) Representative 
Western blot and quantification of protein levels for ER stress markers ATF-6, IRE1α and 
XBP1 in the hippocampus of SAMP8 mice after treatment with sEH inhibitors. Gene 
expression levels were determined by real-time PCR, cytokine protein levels by ELISA 
and SOD1 by immunoblotting. Results are expressed as a MEAN ± SEM and were 
significantly different from the control group. Groups were compared by Student t-test 
or by One-Way ANOVA and post-hoc Dunnett’s, n = 4-6 per group, (*p<0.05, **p<0.01, 
***p<0.001 and ****<0.0001) vs. Control. See partial correlations between selected 
variable in Fig. S2 and Table S7.    
 
Fig. 4. AD hallmarks in both SAMP8 and 5xFAD mice models after treatment with sEH 
inhibitors. (A) and (B) Representative Western blot, and quantifications for p-Tau 
Ser396 and p-Tau Ser404. (C) and (D) Representative Western blot, and quantifications 
for CTFs/APP ratio, sAPPα and sAPPβ. (E) Histological images, and quantification of 
amyloid plaques stained with Thioflavin-S in Wt and 5xFAD. Values in bar graphs are 
adjusted to 100% for a protein of control group from each strain. Results are expressed 
as a MEAN ± SEM and were significantly different from the control group. Groups were 
compared by Student t-test or by One-Way ANOVA and post-hoc Dunnett’s, n = 12 per 
group, (*Significant at p<0.05, **Significant at p<0.01, ***Significant at p<0.001 and 
****Significant at p<0.0001). See partial correlations between selected variable in Fig. 
S2, Fig. S3, Table S7 and Table S8. 
 
Fig. 5. Characterization of the effect of sEH inhibitors and donepezil on cognitive status in 
both SAMP8 and 5xFAD mice models.  (A) Short-term memory evaluation after 2 h 
acquisition trial by Discrimination Index and (B) Long-term memory evaluation after 24 h 
acquisition trial by Discrimination Index after exposure to novel objects. Results are 
expressed as a MEAN ± SEM and were significantly different from the control group. 
Groups were compared by Student t-test or by One-Way ANOVA and post-hoc 
Dunnett’s, n = 12 per group, (*Significant at p<0.05, **Significant at p<0.01, 
***Significant at p<0.001 and ****Significant at p<0.0001). See partial correlations 
between selected variable in Fig. S3, Fig. S4, Table S7 and Table S8. 
 
